Mary Meek
Concepts (101)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Radiology, Interventional | 3 | 2021 | 31 | 0.920 |
Why?
| Early Detection of Cancer | 2 | 2015 | 169 | 0.860 |
Why?
| Embolization, Therapeutic | 2 | 2021 | 88 | 0.800 |
Why?
| Mass Screening | 2 | 2015 | 353 | 0.770 |
Why?
| Radiography, Interventional | 3 | 2016 | 60 | 0.720 |
Why?
| Liver Circulation | 1 | 2019 | 22 | 0.680 |
Why?
| Yttrium Radioisotopes | 1 | 2019 | 9 | 0.680 |
Why?
| Hepatic Artery | 1 | 2019 | 21 | 0.670 |
Why?
| Balloon Occlusion | 1 | 2019 | 18 | 0.660 |
Why?
| Cholelithiasis | 1 | 2018 | 12 | 0.650 |
Why?
| Jaundice, Obstructive | 1 | 2018 | 7 | 0.650 |
Why?
| Embalming | 1 | 2018 | 9 | 0.640 |
Why?
| Lung Neoplasms | 2 | 2015 | 606 | 0.640 |
Why?
| Cadaver | 1 | 2018 | 97 | 0.620 |
Why?
| Radiopharmaceuticals | 1 | 2019 | 209 | 0.620 |
Why?
| Aneurysm, False | 1 | 2018 | 44 | 0.620 |
Why?
| Arteries | 1 | 2018 | 93 | 0.620 |
Why?
| Ultrasonography, Interventional | 1 | 2018 | 136 | 0.590 |
Why?
| Occupational Injuries | 1 | 2016 | 31 | 0.530 |
Why?
| Radiation Protection | 1 | 2016 | 47 | 0.530 |
Why?
| Telangiectasia, Hereditary Hemorrhagic | 3 | 2021 | 9 | 0.510 |
Why?
| Liver Neoplasms | 1 | 2019 | 326 | 0.510 |
Why?
| Radiation Injuries | 1 | 2016 | 113 | 0.490 |
Why?
| Occupational Exposure | 1 | 2016 | 122 | 0.480 |
Why?
| Prenatal Exposure Delayed Effects | 1 | 2016 | 186 | 0.460 |
Why?
| Pregnancy Complications | 1 | 2016 | 382 | 0.390 |
Why?
| Catheters, Indwelling | 1 | 2011 | 58 | 0.390 |
Why?
| Positron-Emission Tomography | 1 | 2013 | 295 | 0.390 |
Why?
| Cross Infection | 1 | 2011 | 95 | 0.370 |
Why?
| Catheterization, Central Venous | 1 | 2011 | 86 | 0.370 |
Why?
| Prosthesis-Related Infections | 1 | 2011 | 104 | 0.360 |
Why?
| Tomography, X-Ray Computed | 1 | 2013 | 1159 | 0.310 |
Why?
| Humans | 14 | 2021 | 49974 | 0.210 |
Why?
| Cerebrovascular Trauma | 1 | 2021 | 10 | 0.200 |
Why?
| Cryosurgery | 1 | 2021 | 36 | 0.190 |
Why?
| Vascular Diseases | 1 | 2021 | 75 | 0.180 |
Why?
| Wounds, Nonpenetrating | 1 | 2021 | 81 | 0.180 |
Why?
| Retrospective Studies | 4 | 2021 | 6108 | 0.170 |
Why?
| Aged | 3 | 2019 | 9310 | 0.170 |
Why?
| Combined Modality Therapy | 1 | 2021 | 637 | 0.170 |
Why?
| Ultrasonography, Doppler, Color | 1 | 2018 | 33 | 0.160 |
Why?
| Risk Factors | 2 | 2019 | 3613 | 0.150 |
Why?
| Male | 5 | 2021 | 25241 | 0.150 |
Why?
| Treatment Outcome | 3 | 2021 | 5141 | 0.150 |
Why?
| Phantoms, Imaging | 1 | 2018 | 121 | 0.150 |
Why?
| Female | 5 | 2021 | 26472 | 0.140 |
Why?
| Radiometry | 1 | 2016 | 123 | 0.130 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 989 | 0.130 |
Why?
| Adult | 3 | 2021 | 13236 | 0.120 |
Why?
| Middle Aged | 3 | 2021 | 12069 | 0.110 |
Why?
| False Positive Reactions | 1 | 2013 | 63 | 0.110 |
Why?
| Tumor Burden | 1 | 2013 | 132 | 0.110 |
Why?
| Arkansas | 2 | 2015 | 1977 | 0.100 |
Why?
| Cost-Benefit Analysis | 1 | 2013 | 274 | 0.100 |
Why?
| Teaching | 1 | 2013 | 116 | 0.100 |
Why?
| Patient Selection | 1 | 2013 | 253 | 0.100 |
Why?
| Aged, 80 and over | 1 | 2019 | 3129 | 0.100 |
Why?
| Radiology | 1 | 2013 | 131 | 0.100 |
Why?
| Phlebography | 1 | 2011 | 61 | 0.100 |
Why?
| Infection Control | 1 | 2011 | 50 | 0.100 |
Why?
| Neoplasm Staging | 1 | 2013 | 740 | 0.090 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2013 | 549 | 0.090 |
Why?
| Prosthesis Design | 1 | 2011 | 237 | 0.090 |
Why?
| Practice Guidelines as Topic | 1 | 2013 | 449 | 0.090 |
Why?
| Curriculum | 1 | 2013 | 401 | 0.090 |
Why?
| Smoking | 1 | 2013 | 511 | 0.090 |
Why?
| Pregnancy | 1 | 2016 | 2607 | 0.080 |
Why?
| Internship and Residency | 1 | 2013 | 443 | 0.080 |
Why?
| Mediastinum | 1 | 2021 | 22 | 0.050 |
Why?
| Administration, Intravenous | 1 | 2021 | 69 | 0.050 |
Why?
| Vincristine | 1 | 2021 | 89 | 0.050 |
Why?
| Angiography | 1 | 2021 | 126 | 0.050 |
Why?
| Axilla | 1 | 2021 | 89 | 0.050 |
Why?
| Prednisone | 1 | 2021 | 99 | 0.050 |
Why?
| Pelvis | 1 | 2021 | 68 | 0.050 |
Why?
| Research | 1 | 2021 | 110 | 0.050 |
Why?
| Cyclophosphamide | 1 | 2021 | 165 | 0.050 |
Why?
| Epistaxis | 1 | 2020 | 11 | 0.050 |
Why?
| Consensus | 1 | 2021 | 148 | 0.050 |
Why?
| Genetic Diseases, Inborn | 1 | 2020 | 24 | 0.050 |
Why?
| Anemia | 1 | 2020 | 68 | 0.040 |
Why?
| Gastrointestinal Hemorrhage | 1 | 2020 | 78 | 0.040 |
Why?
| Hemorrhage | 1 | 2021 | 197 | 0.040 |
Why?
| Doxorubicin | 1 | 2021 | 233 | 0.040 |
Why?
| Arteriovenous Malformations | 1 | 2020 | 67 | 0.040 |
Why?
| Vascular Surgical Procedures | 1 | 2021 | 165 | 0.040 |
Why?
| Activin Receptors, Type II | 1 | 2015 | 5 | 0.030 |
Why?
| Smad4 Protein | 1 | 2015 | 6 | 0.030 |
Why?
| Congresses as Topic | 1 | 2015 | 44 | 0.030 |
Why?
| Receptors, Cell Surface | 1 | 2015 | 122 | 0.030 |
Why?
| Liver | 1 | 2020 | 1115 | 0.030 |
Why?
| Antigens, CD | 1 | 2015 | 219 | 0.030 |
Why?
| Planning Techniques | 1 | 2012 | 9 | 0.030 |
Why?
| Economic Competition | 1 | 2012 | 9 | 0.030 |
Why?
| Competitive Behavior | 1 | 2012 | 11 | 0.030 |
Why?
| Marketing of Health Services | 1 | 2012 | 8 | 0.030 |
Why?
| Practice Management, Medical | 1 | 2012 | 12 | 0.030 |
Why?
| Efficiency, Organizational | 1 | 2012 | 42 | 0.030 |
Why?
| Models, Organizational | 1 | 2012 | 59 | 0.030 |
Why?
| Health Care Costs | 1 | 2012 | 170 | 0.020 |
Why?
| Child | 1 | 2020 | 6847 | 0.020 |
Why?
|
|
Meek's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|